These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38708485)

  • 1. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.
    Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P
    Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.
    Sardh E; Balwani M; Rees DC; Anderson KE; Jia G; Sweetser MT; Wang B
    Orphanet J Rare Dis; 2024 Oct; 19(1):365. PubMed ID: 39363243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria.
    Bujold KE; Kasher N; McKiernan C
    J Pediatr Hematol Oncol; 2024 Oct; 46(7):e524-e527. PubMed ID: 39177802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Givosiran: A Review in Acute Hepatic Porphyria.
    Syed YY
    Drugs; 2021 May; 81(7):841-848. PubMed ID: 33871817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
    Agarwal S; Simon AR; Goel V; Habtemariam BA; Clausen VA; Kim JB; Robbie GJ
    Clin Pharmacol Ther; 2020 Jul; 108(1):63-72. PubMed ID: 31994716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.
    de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Givosiran in acute intermittent porphyria: A personalized medicine approach.
    Poli A; Schmitt C; Moulouel B; Mirmiran A; Talbi N; Rivière S; Cerutti D; Bouchoule I; Faivre A; Grobost V; Douillard C; Duchêne F; Fiorentino V; Dupré T; Manceau H; Peoc'h K; Puy H; Lefebvre T; Gouya L
    Mol Genet Metab; 2022 Mar; 135(3):206-214. PubMed ID: 35058124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran.
    To-Figueras J; Wijngaard R; García-Villoria J; Aarsand AK; Aguilera P; Deulofeu R; Brunet M; Gómez-Gómez À; Pozo OJ; Sandberg S
    J Inherit Metab Dis; 2021 Jul; 44(4):961-971. PubMed ID: 33861472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria].
    Stölzel U
    Z Gastroenterol; 2020 Aug; 58(8):785. PubMed ID: 32785915
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
    Ventura P; Bonkovsky HL; Gouya L; Aguilera-Peiró P; Montgomery Bissell D; Stein PE; Balwani M; Anderson DKE; Parker C; Kuter DJ; Monroy S; Oh J; Ritchie B; Ko JJ; Hua Z; Sweetser MT; Sardh E;
    Liver Int; 2022 Jan; 42(1):161-172. PubMed ID: 34717041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute intermittent porphyria, givosiran, and homocysteine.
    Fontanellas A; Ávila MA; Arranz E; Enríquez de Salamanca R; Morales-Conejo M
    J Inherit Metab Dis; 2021 Jul; 44(4):790-791. PubMed ID: 34145602
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP).
    Massachi S; Epstein J; Hurd J; Bonkovsky HL
    J Med Econ; 2020 Dec; 23(12):1441-1449. PubMed ID: 33043761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran.
    Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B
    J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?
    Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK
    Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy.
    Majeed CN; Ma CD; Xiao T; Rudnick S; Bonkovsky HL
    Drug Des Devel Ther; 2022; 16():1827-1845. PubMed ID: 35734365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.